THERAPY DOSSIER · th-1b7819b77b33

Exogenous pulmonary surfactant (Survanta)

Biologic · Surfactant agent: replaces endogenous surfactant in deficiency and lowers surface tension at the air-liquid interface of alveolar surfaces (ChEMBL mechanism, no molecular target assigned). Survanta is the trade name of beractant.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Surfactant agent: replaces endogenous surfactant in deficiency and lowers surface tension at the air-liquid interface of alveolar surfaces (ChEMBL mechanism, no molecular target assigned). Survanta is the trade name of beractant.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: 1991
Development stage: Not recorded
ChEMBL record: CHEMBL1201624 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Survanta; Beractant; Surfactant TA; A-60386X
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04199364 ↗PHASE4unknown

Comparison of Two FiO2 Thresholds for Surfactant Administration in Preterm Infants With RDS

Respiratory Distress Syndrome

Enrolment: 200 · Results not recorded

NCT00005774 ↗PHASE3terminated

Early Surfactant Followed by Nasal CPAP to Reduce Mechanical Ventilation in Infants 1250-2000 g With RDS

Respiratory Distress Syndrome · Infant, Newborn

Enrolment: 61 · Results not recorded

NCT00233324 ↗PHASE3completed

Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants

Infant, Newborn, Diseases · Bronchopulmonary Dysplasia · Retinopathy of Prematurity

Enrolment: 1316 · Results not recorded

NCT05711966 ↗NAunknown

Comparison of IN-REC-SUR-E and LISA in Preterm Neonates With RDS (IN-REC-LISA)

Respiratory Distress Syndrome · Bronchopulmonary Dysplasia

Enrolment: 381 · Results not recorded

NCT02825953 ↗NAunknown

Surfactant Administration by Aerosolisation in Spontaneously Breathing Premature Infants With RDS

Respiratory Distress Syndrome

Enrolment: 75 · Results not recorded

NCT06758492 ↗Phase not recordedrecruiting

Video Laryngoscopy Versus Direct Laryngoscopy for Insertion of a Thin Catheter for Surfactant Administration in Newborns

Respiratory Distress Syndrome (Neonatal)

Enrolment: 600 · Results not recorded

Preclinical evidence 2

1 studies reported at therapy level; 2 evidence entries itemised.

PMID 2732176 ↗1989Reported benefit

Effect of exogenous surfactant instillation on experimental acute lung injury.

RatChemical/toxinIntratracheal instillationAfter NNNMU injury

Model: N-nitroso-N-methylurethane (NNNMU) induced acute lung injury in rats with chronic indwelling arterial catheters

Surfactant instillation improved oxygenation, reduced mortality to control values and restored the phospholipid-to-protein ratio, surface activity and individual phospholipid percentages, except phosphatidylglycerol, towards control values.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

PMID 16055934 ↗2005

Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury

RatChemical/toxin

Extraction: mesh. Machine-extracted fields require source verification.

Loading the evidence…